- Home
- VNO vs HALO Comparison
VNO vs HALO Comparison
Compare VNO & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VNO | HALO |
|---|---|---|
| Founded | 1946 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.3B | 7.4B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | VNO | HALO |
|---|---|---|
| Price | $34.48 | $64.63 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 12 | 12 |
| Target Price | $38.33 | ★ $73.33 |
| AVG Volume (30 Days) | 1.5M | ★ 2.5M |
| Earning Date | 11-03-2025 | 11-03-2025 |
| Dividend Yield | ★ 2.09% | N/A |
| EPS Growth | N/A | ★ 56.68 |
| EPS | 4.20 | ★ 4.74 |
| Revenue | ★ $1,903,939,000.00 | $1,242,852,000.00 |
| Revenue This Year | N/A | $34.83 |
| Revenue Next Year | $2.19 | $24.84 |
| P/E Ratio | ★ $8.42 | $13.14 |
| Revenue Growth | 1.75 | ★ 31.19 |
| 52 Week Low | $29.68 | $46.26 |
| 52 Week High | $45.53 | $79.50 |
Technical Indicators
Market Signals| Indicator | VNO | HALO |
|---|---|---|
| Relative Strength Index (RSI) | 42.32 | 44.64 |
| Support Level | $34.27 | $61.23 |
| Resistance Level | $35.68 | $63.26 |
| Average True Range (ATR) | 1.00 | 2.25 |
| MACD | 0.04 | -0.34 |
| Stochastic Oscillator | 18.45 | 26.22 |
Price Performance
Historical ComparisonAbout VNO Vornado Realty Trust
Vornado owns and has an ownership interest in Class A office and retail properties highly concentrated in Manhattan, with additional properties in San Francisco and Chicago. It operates as a real estate investment trust.
About HALO Halozyme Therapeutics Inc.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.